CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue has announced today the public launch of its UltiMapper™ portfolio of reagents enabling the highest throughput of whole-slide, protein biomarker analysis and spatial detection in tissue, at high level of multiplexing, using instrumentation and software solutions currently found in most Immuno-Histochemistry laboratories. With UltiMapper I/O reagents, Ultivue introduces a fully optimized, ready-to-use portfolio of kits enabling fast, holistic profiling and characterization of tumor immuno-oncology markers in Formalin-Fixed, Paraffin-Embedded (FFPE) samples. Dr. Michael Natan, Ultivue’s Chief Executive Officer, “We are delighted to be shipping kits to customers who’ve recognized the enormous value our reagents provide in I/O drug development, and look forward to a very significant expansion of our I/O portfolio later this year to meet the demand of immuno-oncology translational and clinical research labs. Beyond that, Ultivue will expand its offerings to oncology, inflammation and auto-immune research areas. In addition to UltiMapper kit reagents, scientists across the world have access, through Ultivue’s best-in-class Fee for Service laboratory, to highly customizable, multiplex assays that incorporate any protein of interest or proprietary marker antibody.”
UltiMapper reagents and service offerings are powered by Ultivue’s proprietary InSituPlex™ technology which combines DNA-barcoded antibodies with unique, complementary, fluorescent DNA barcodes, in a single slide staining, signal amplification, and imaging step assay. Prior to launch, UltiMapper reagents have been extensively tested by a diverse and representative set of leading immuno-oncology Pharma, Cancer Research Centers and Clinical Research Organizations. “Exceptional quality assay, straightforward implementation, ease of use of both manual and automated protocols, very relevant content for tumor immuno-profiling and assay reproducibility, are the most commonly shared comments on our UltiMapper kits. Early adopters also commented on the unbiased biology analysis, enabled by whole slide imaging, which supports complex biomarker analysis beyond a few, limited regions of interest,” says Philippe Mourere, SVP Commercial Operations.
Ultivue also announces an upcoming webinar presented on July 18th, 2018, at 11:00 am EDT, in collaboration with Leica Biosystems and Indica Labs Inc., and entitled “From Staining to Analysis: End-to-End Application of UltiMapper Kits for Multiplexed Immuno-Profiling in FFPE Tumor Samples”. During this 60-minute webinar, attendees will learn about the InSituPlex technology, the development and validation of UltiMapper kit reagents, the use of the assays in a highly automated environment, and the analysis of whole slide images to extract complex information such as cell counts, marker co-localization and proximity, providing insights into complex biological questions posed by the tumor micro-environment.
Founded by two core faculty from the Wyss Institute at Harvard University˗ David Walt, a world-leading expert in biomolecular analysis, and Peng Yin, a pioneer in DNA nanotechnology˗ Ultivue is a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue’s proprietary solutions will enable researchers and clinicians to realize the promise of personalized medicine through better matching of patients to therapeutic options. The company is launching products and services that seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications. Ultivue is based in Cambridge, MA.
To learn more, visit www.ultivue.com